Table 1.
Analysis of clinical data of WEBINO patients.
| Case (references) | Patient | Age | Gender | Neuro-ocular signs | Etiology | Occlusion site | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aa | Bb | Cc | Dd | Ee | Ff | Gg | Hh | ||||||
| 1. Inocencio and Ballecer (1985) | 1 | 24 | M | Y | Y | Y | N | N | N | N | N | CNS MTI | Mid, Pons |
| 2. Lana et al. (1990) | 1 | 35 | F | Y | Y | Y | N | N | N | N | N | CNS vasculitis | – |
| 3. Fay and Strominger (1999) | 1 | 33 | M | Y | Y | Y | N | N | N | N | N | CNS Cry | Mid |
| 4. Korkmaz et al. (2002) | 1 | 14 | F | Y | Y | N | N | N | N | N | N | CIDP | – |
| 5. Ozer et al. (2005) | 1 | 15 | M | Y | – | – | – | – | – | Y | N | DAD | Mid, Pons |
| 6. Chen and Lin (2007) | 4 | 66 | M | Y | Y | N | N | Y | N | N | N | CI | Mid |
| 84 | M | Y | Y | N | N | Y | N | N | N | CI | Mid, Pons | ||
| 51 | F | Y | Y | N | N | N | N | N | N | Hyd, brainstem neoplasms | Mid, Pons | ||
| 65 | F | Y | Y | Y | N | N | N | N | N | CI | Pons | ||
| 7. Kim et al. (2008) | 1 | 78 | M | Y | Y | Y | N | Y | N | N | N | CI | Mid |
| 8. Matsumoto et al. (2008) | 1 | 72 | M | Y | Y | Y | N | Y | N | N | N | PSP | Mid |
| 9. Ushio et al. (2008) | 1 | 72 | M | Y | Y | Y | N | Y | N | N | N | PSP | Mid |
| 10. Jacob et al. (2010) | 1 | 67 | M | Y | – | – | – | – | N | N | N | Hyd, SAH | – |
| 11. Sierra-Hidalgo et al. (2010) | 1 | 55 | F | Y | Y | N | Y | Y | N | Y | N | CI | Mid |
| 12. Shinoda et al. (2011) | 1 | 19 | F | Y | Y | N | N | N | N | Y | N | NMOSD | Mid |
| 13. Beh and Frohman (2012) | 1 | 69 | M | Y | Y | Y | N | Y | N | N | N | CI | Mid, Pons |
| 14. Jadhav and Prasad (2012) | 1 | 41 | M | Y | Y | N | N | N | Y | N | N | Hyd, CM | – |
| 15. Sakamoto et al. (2012) | 1 | 64 | M | Y | Y | Y | N | N | N | N | N | CI | Pons |
| 16. Bar et al. (2014) | 1 | 12 | F | Y | Y | N | N | Y | Y | N | N | Dem | Mid |
| 17. Chakravarthi et al. (2014) | 1 | 64 | F | Y | Y | Y | N | Y | N | N | N | CI | Mid |
| 18. Mathis et al. (2014) | 1 | 68 | M | Y | Y | Y | N | N | N | N | N | CI | Pons |
| 19. Muralidhar et al. (2014) | 1 | 35 | M | Y | Y | N | N | N | N | N | N | Alcohol | - |
| 20. Nakajima et al. (2014) | 1 | 68 | M | Y | Y | Y | Y | Y | N | N | N | CI | Mid, Pons |
| 21. de Mora et al. (2014) | 1 | 57 | M | Y | Y | Y | N | N | Y | N | N | CI, Neurosyphilis | Mid |
| 22. Toufeeq and Dave (2014) | 1 | 13 | M | Y | Y | Y | N | Y | Y | Y | N | Pineal tumor | Mid |
| 23. Agarwal et al. (2015) | 1 | 19 | F | Y | Y | Y | N | Y | Y | N | Y | CI | Mid, Pons |
| 24. Ljevak et al. (2015) | 1 | 53 | M | Y | Y | N | Y | Y | N | Y | Y | CI | Mid |
| 25. Man et al. (2015) | 1 | 84 | M | Y | Y | Y | N | Y | N | N | N | CI | Mid |
| 26. de Souza et al. (2017) | 1 | 60 | F | Y | Y | Y | N | Y | N | Y | N | PSP | Mid |
| 27. Sajjadi et al. (2017) | 1 | 38 | M | Y | Y | Y | N | N | N | N | N | – | – |
| 28. Zou and Chen, 2017) | 1 | 70 | F | Y | Y | Y | Y | Y | N | N | N | NMOSD | Mid |
| 29. Papageorgiou et al. (2018) | 1 | 65 | M | Y | Y | N | N | N | N | N | N | CI | Mid |
| 30. Keereman et al. (2018) | 1 | 25 | F | Y | Y | N | Y | N | N | Y | N | Hyd | – |
| 31. Matsumoto et al. (2019) | 1 | 81 | M | N | Y | Y | N | Y | N | N | N | PSP | Mid |
| 32. Yazdi et al. (2020) | 1 | 57 | M | Y | Y | Y | N | Y | N | N | N | PSP | Mid, Pons |
| 33. Vázquez-Justes et al. (2020) | 1 | 68 | M | N | Y | N | N | N | N | N | N | Ischemic lesion | Mid |
| 34. Im et al. (2020) | 1 | 62 | F | N | Y | N | N | N | N | N | N | Stroke | Pons |
| 35. Petrik et al. (2021) | 1 | 55 | M | Y | N | N | N | N | N | N | N | CH | Pons |
| 36. Jo et al. (2021) | 1 | – | – | – | – | – | – | – | – | – | – | CI | Mid |
| 37. Sinha et al. (2021) | 1 | 48 | F | N | Y | N | Y | N | Y | Y | N | CH | Brainstem |
| 38. Ansari et al. (2021) | 1 | 45 | F | Y | Y | N | N | N | N | N | N | irEA | – |
| 39. Wako et al. (2022) | 1 | 85 | M | Y | Y | Y | N | N | N | N | N | CES | Mid, Pons, Cer |
Aa, Exotropia in the first eye-position; Bb, Bilateral Intraocular Disorders; Cc, Convergence barrier; Dd, Blepharoptosis; Ee, Vertical gaze disorder; Ff, Vertical nystagmus; Gg, Pupillary anomalies; Hh, Reversed dip. M, Male; F, Female; Y, yes; N, No; CI, Cerebral infarction; CH, Cerebral hemorrhage; Mid, Midbrain; Cer, cerebellum; Cry, Cryptococcosis infection; MTI, Mycobacterium tuberculosis infection; CNS, Central nervous system; CIDP, Chronic inflammatory demyelinating polyradiculoneuropathy; Hyd, Hydrocephalus; DAD, Diffuse axonal damage; PSP, Progressive superanuclear palsy; CES, cardioembolic stroke; SAH, Subarachnoid hemorrhage; NMOSD, Neuromyelitis optica spectrum disorders; CM, Cryptococcal meningitis; Dem, Demyelinating Diseases; irEA, Immune related adverse event.